Get the Stockscreener App
0.89
2.99%
-0.0274
Pharmacyte Biotech Inc stock is traded at $0.89, with a volume of 34,764.
It is down -2.99% in the last 24 hours and down -14.42% over the past month.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
See More
Previous Close:
$0.9174
Open:
$0.9
24h Volume:
34,764
Relative Volume:
0.35
Market Cap:
$6.05M
Revenue:
-
Net Income/Loss:
$-1.13M
P/E Ratio:
-1.9386
EPS:
-0.4591
Net Cash Flow:
$-4.60M
1W Performance:
-9.46%
1M Performance:
-14.42%
6M Performance:
-26.45%
1Y Performance:
-48.85%
1-Day Range:
$0.88
$0.9174
1-Week Range:
$0.88
$1.001
52-Week Range:
$0.80
$1.94
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Name
Pharmacyte Biotech Inc
Sector
Industry
Phone
(917) 595.2850
Address
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.50 | 4.21B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.99 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.825 | 217.47M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2288 | 502.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.3695 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Stock (PMCB) Latest News
What Fibonacci levels say about PharmaCyte Biotech Inc. reboundWeekly Trade Summary & Growth Oriented Trading Recommendations - newser.com
Can PharmaCyte Biotech Inc. recover in the next quarter2025 Top Gainers & Fast Entry Momentum Alerts - newser.com
Will PharmaCyte Biotech Inc. stock reach all time highs in 2025Market Volume Summary & Safe Capital Growth Tips - newser.com
What sentiment indicators say about PharmaCyte Biotech Inc. stockQuarterly Profit Review & Technical Pattern Based Signals - newser.com
Can PharmaCyte Biotech Inc. stock hit record highs againGap Down & Low Drawdown Momentum Ideas - newser.com
How PharmaCyte Biotech Inc. stock performs in stagflationEntry Point & Consistent Growth Equity Picks - newser.com
Combining machine learning predictions for PharmaCyte Biotech Inc.Portfolio Update Report & Weekly High Potential Stock Alerts - newser.com
Developing predictive dashboards with PharmaCyte Biotech Inc. dataJuly 2025 WrapUp & Verified Chart Pattern Trade Signals - newser.com
PharmaCyte Biotech Amends Equity Incentive Plan - TipRanks
PMCB shareholders approve Nasdaq 5635(d) issuance and plan increase - Stock Titan
Statistical indicators supporting PharmaCyte Biotech Inc.’s strengthTrend Reversal & Free Safe Capital Growth Stock Tips - newser.com
Top chart patterns to watch in PharmaCyte Biotech Inc.2025 Trading Recap & Long Hold Capital Preservation Tips - newser.com
Applying chart zones and confluence areas to PharmaCyte Biotech Inc.Gap Up & Stepwise Trade Execution Plans - newser.com
What indicators show strength in PharmaCyte Biotech Inc.Product Launch & Fast Exit and Entry Strategy Plans - newser.com
Is PharmaCyte Biotech Inc. forming a bottoming baseMarket Growth Summary & Capital Protection Trading Alerts - newser.com
What to do if you’re stuck in PharmaCyte Biotech Inc.Bond Market & Weekly Return Optimization Alerts - newser.com
How PharmaCyte Biotech Inc. stock benefits from global expansionJuly 2025 Summary & Low Risk Growth Stock Ideas - Fundação Cultural do Pará
Is PharmaCyte Biotech Inc. stock attractive for passive investors2025 Top Decliners & Expert Approved Trade Ideas - newser.com
Pharmacyte Biotech Inc Stock (PMCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):